Stock IKNA IKENA ONCOLOGY, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Ikena Oncology, Inc.

Equities

IKNA

US45175G1085

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-29 pm EDT 		5-day change 1st Jan Change
1.33 USD +2.31% Intraday chart for Ikena Oncology, Inc. +2.31% -32.49%
Mar. 12 Ikena Oncology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Mar. 12 North American Morning Briefing : Inflation Data -2- DJ

Evolution of the average Target Price on Ikena Oncology, Inc.

Price target over the last 5 years

History of analyst recommendation changes

b0fd48d8ebdf7fac98f1d42.dteDIR22ycdwJshZj9O2_txIa8ql__77QfZsXtGliCY.T5rRSFWDh4MAdqFpzon8iJ9lWefAoK60Dbw4H57W7l4mv_sXMNWu9R4ThQ~89c897def8fbc8bf5f5763a25c9577fa

Analyst Recommendations on Ikena Oncology, Inc.

HC Wainwright Adjusts Ikena Oncology Price Target to $11 From $18, Maintains Buy Rating MT
Wedbush Lowers Ikena Oncology's Price Target to $8 From $11, Moves Estimates Launch Timings for IK-930; Maintains Outperform Rating MT
Wedbush Starts Ikena Oncology at Outperform With $11 Price Target MT
Credit Suisse Adjusts Ikena Oncology's Price Target to $13 From $16, Keeps Outperform Rating MT
Credit Suisse Adjusts Ikena Oncology's Price Target to $16 From $18, Keeps Outperform Rating MT
HC Wainwright Adjusts Ikena Oncology's Price Target to $22 From $26, Keeps Buy Rating MT
Credit Suisse Lowers Ikena Oncology's Price Target to $18 From $20, Keeps Outperform Rating MT
Credit Suisse Lowers Ikena Oncology's Price Target to $20 from $24, Keeps Outperform Rating MT
HC Wainwright Adjusts Price Target on Ikena Oncology to $26 From $25, Reiterates Buy Rating MT
History shows stocks can weather rate hike cycle RE
HC Wainwright Initiates Coverage on Ikena Oncology With Buy Rating, $25 Price Target MT
IKENA ONCOLOGY : Credit Suisse Lowers Ikena Oncology's Price Target to $27 From $30 on Expense, Forecast Adjustments; Outperform Rating Kept MT
IKENA ONCOLOGY : Cowen Initiates Ikena Oncology With Outperform Rating MT
IKENA ONCOLOGY : William Blair Initiates Ikena Oncology at Outperform Rating MT
IKENA ONCOLOGY : Credit Suisse Starts Ikena Oncology at Outperform with $30 Price Target, Notes 'Attractive' Novel Cancer Therapy Candidates MT
IKENA ONCOLOGY : Jefferies Initiates Coverage on Ikena Oncology With Buy Rating MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
1.33 USD
Average target price
8.333 USD
Spread / Average Target
+526.57%
High Price Target
11 USD
Spread / Highest target
+727.07%
Low Price Target
6 USD
Spread / Lowest Target
+351.13%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Ikena Oncology, Inc.

HC Wainwright
Wedbush
Credit Suisse
Jefferies & Co.
William Blair & Co.

Ratings for Ikena Oncology, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. IKNA Stock
  4. Consensus Ikena Oncology, Inc.